Flynise

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Flynise

Quick Facts

Property Description
Active ingredient Desloratadine
Form Tablet, Orodispersible tablet, Oral solution
Pharmacological class Antihistamine (Second-generation)
General purpose Alleviates symptoms of allergic conditions
Origin Synthetic compound (Active metabolite)

Flynise: Classification and Therapeutic Role

Flynise is a synthetic medicinal product containing Desloratadine, classified as a second-generation, tricyclic antihistamine used for systemic treatment of allergic symptoms. The drug is formally designated within the major pharmacological class of Antihistamines, indicating its primary role is to block the effects of histamine in the body. Desloratadine's specific molecular design ensures it is a nonsedating compound because it does not readily cross the blood-brain barrier. This widely recognized property means the medication provides essential relief from common allergic symptoms, such as an itchy nose or persistent hives, without causing the cognitive impairment often associated with older agents.


Active Ingredient and Compound Origin

The medicinal entity is based on the potent active ingredient Desloratadine, a substance that is a synthetic compound derived from the parent drug loratadine. Desloratadine functions as the principal, active metabolite of loratadine, which is the key component responsible for the therapeutic effect. Desloratadine provides relief from the symptoms of allergic rhinitis and chronic idiopathic urticaria. This clinical recognition supports the drug’s utility in sustained symptom management for adults and adolescents. Flynise is manufactured as a single active ingredient product, incorporated with either oral solid excipients for the tablet forms or an aqueous base for the liquid form.


Available Forms and Administration Type

Flynise is available for oral administration in various dosage forms, providing flexible options for therapeutic delivery. The preparation is notable for its orodispersible tablet form, which is designed to rapidly dissolve upon contact with saliva, offering a distinct advantage for individuals who may have difficulty swallowing conventional pills. The product is also available as standard tablets and an oral solution. This multi-form availability affirms the product's identity as a versatile pharmaceutical option suited for systemic use in managing a range of allergy symptoms.

Regulatory References

  1. MedlinePlus Drug Information: Desloratadine
  2. European Medicines Agency (EMA)
  3. Aerius EPAR - Summary for the public

What side effects are possible with Flynise?

Flynise (desloratadine) is generally well-tolerated, with a side effect profile similar to placebo in many clinical trials. However, like all medications, it can cause adverse effects in some individuals.

Common Side Effects

These are the most frequently reported side effects and typically do not require medical attention unless persistent or bothersome:

  • Headache
  • Fatigue or unusual tiredness
  • Dry mouth
  • Sore throat (Pharyngitis)

Less commonly reported effects include dizziness, nausea, dyspepsia (indigestion), and muscle pain (myalgia).

Serious Side Effects and Warnings

While very rare, Flynise can cause serious adverse effects. Seek immediate medical attention if you experience signs of a severe allergic reaction (anaphylaxis), such as:

  • Swelling of the face, tongue, throat, or lips (Angioedema)
  • Difficulty breathing or wheezing
  • Rash or hives
  • Fast or irregular heartbeat (Tachycardia or palpitations)
  • Seizures
  • Liver inflammation or abnormal liver function test results, which may present as jaundice (yellowing of the skin or eyes).

Contraindications and Precautions

Flynise is contraindicated in patients with a known hypersensitivity to desloratadine, loratadine, or any ingredient in the formulation. Caution is advised, and dose adjustment may be necessary in patients with severe kidney or liver impairment, as these conditions can increase the concentration of the medication in the body. If you are pregnant or breastfeeding, consult your healthcare provider, as the medication is generally not recommended during these periods.

Although Flynise is considered a non-drowsy antihistamine, individual responses can vary. Caution is recommended when operating machinery or driving until you are aware of how the medication affects you. Concurrent use of alcohol may increase the risk of drowsiness.

Overdose and Emergency Response

Flynise Overdose and when to seek help

The regulatory documentation for Desloratadine overdose indicates that the profile of symptoms observed is generally similar to those seen at therapeutic doses, but the magnitude of the effects can be higher. Officially documented manifestations may include central nervous system effects such as somnolence (drowsiness) or cardiac effects like tachycardia and palpitations.

When to Seek Immediate Medical Attention

Government regulatory authorities explicitly mandate that individuals must seek immediate medical attention for any suspected overdose. Immediate contact with emergency services is required if the person has collapsed, experiences a seizure, or has trouble breathing. Immediate medical review is also mandated if a severe allergic reaction (such as swelling or difficulty breathing) occurs.

Officially Documented Complications and Management

Serious outcomes reported via post-marketing surveillance include seizures and cardiac effects such as QT prolongation and arrhythmia, with these risks noted especially in the pediatric population. Patients with severe kidney or liver impairment may also face higher risk due to documented increases in drug exposure. Management of overdose consists of symptomatic and supportive treatment, as officially described. Regulatory information states clearly that no specific antidote is known for Desloratadine overdose. Standard measures to remove unabsorbed substance should be considered, though the drug is not eliminated by haemodialysis.

Therapeutic Uses of Flynise

Flynise is commonly used to provide symptomatic support for allergic conditions in adults, adolescents, and children, addressing symptoms that interfere with daily functioning. The medication is applied in addressing conditions marked by persistent or recurrent symptoms, and its role may assist with easing the symptoms of allergic rhinitis and urticaria.

Quick Fact: Support for Combined Allergic Symptoms

The medication may be part of symptomatic management of conditions characterized by periods of heightened symptoms, namely seasonal allergic rhinitis (hay fever), perennial allergic rhinitis, and Chronic Idiopathic Urticaria (hives). It helps address symptom clusters related to inflammatory or irritative states, such as sneezing, runny nose, nasal congestion, itchy eyes, and distressing skin itching. This provides supportive relief that contributes to improved comfort and assists with maintaining functional stability during symptomatic periods.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Official Eligibility Profile: Who Can and Cannot Use Flynise (Desloratadine)

This information reflects eligibility criteria established by authoritative government regulatory agencies (e.g., FDA, EMA) for the active substance desloratadine.


Absolute Exclusions (Contraindications)

Rule Population Excluded
Hypersensitivity Patients with a known allergy to desloratadine, any excipients in the specific formulation, or to loratadine (its related drug).

Conditional and Restricted Use (Special Populations)

  • Age-Based Limits: Tablet formulations are generally not recommended for children under 12 years of age. Eligibility for younger children depends on the specific formulation (e.g., oral solution) and regulatory approval, sometimes extending to children as young as 6 months.
  • Organ Function Impairment: Patients with severe kidney (renal) or liver (hepatic) impairment must use the medicine with caution. Dosage adjustment may be required in adults due to altered drug clearance.
  • Pregnancy and Breastfeeding: Use is generally not recommended during pregnancy as a precautionary measure. Breastfeeding patients are advised to either discontinue nursing or stop using the drug, as the substance passes into breast milk.
  • Seizure History: Caution is advised for patients with a medical or familial history of seizures due to a potential increased susceptibility.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Flynise (Desloratadine) is defined by official government regulatory documents detailing specific pharmacokinetic and pharmacodynamic outcomes, without providing clinical recommendations.

Documented Pharmacokinetic Interactions

Co-administration of Flynise with specific medicinal products results in a pharmacokinetic interaction that formally increases the systemic concentration (AUC and Cmax) of desloratadine and its active metabolite. These interacting agents explicitly listed in regulatory documents include the antifungal Ketoconazole, the antibiotics Erythromycin and Azithromycin, the H2-receptor antagonist Cimetidine, and the antidepressant Fluoxetine. No substances are documented in official regulatory labels to significantly decrease the exposure of desloratadine.

Substance Interactions and Restrictions

  • Alcohol: Clinical studies formally documented that Flynise did not potentiate the performance-impairing effects of alcohol. However, regulatory post-marketing data includes reports of alcohol intolerance and intoxication.
  • Food and Timing: Official regulatory text confirms that the product may be administered independently of meals, as food does not affect its absorption. There are no mandatory time separation requirements for Flynise from other medicines.
  • Hypersensitivity: Official labels state a restriction against use for individuals with known hypersensitivity to desloratadine or the parent compound, loratadine.

Population-Specific Notes

Patients with documented severe renal impairment or hepatic impairment are noted to experience increased systemic exposure to desloratadine due to reduced clearance from the body.

Mechanism of Action

How Flynise Works: Mechanism of Action

Selective Targeting of Histamine H1 Receptors (Inverse Agonism)

Flynise acts by highly selective binding to and inactivation of the peripheral Histamine H1 receptors ( H1 R). Functioning as an inverse agonist, the drug stabilizes these receptors in an inactive conformation, preventing the signal that histamine normally transmits to effector cells.


Dampening the Peripheral Allergic Cascade

By occupying the H1 R, Flynise suppresses the signaling sequence triggered by H1 R activation. This halts the intracellular cascade that leads to certain physiological changes and results in decreased microvascular permeability.


High Peripheral Selectivity and Modulation of Vascular Responses

Flynise is characterized by a low capacity to pass the blood-brain barrier. This peripheral selectivity restricts its mechanistic influence on CNS pathways that regulate arousal, confining its primary action to non-neural tissues and the peripheral nervous system. The mechanism induces physiological modulation through H1 R blockade, which promotes stabilization of microvascular tone and suppresses afferent sensory nerve signaling.

Dosage and Administration Information

How Flynise is Used: Official Administration Guidelines

Flynise (desloratadine) is used solely via the oral route for systemic treatment, ensuring the medicine is absorbed through the digestive system. The official administration protocol is designed for fixed, once-daily dosing to provide continuous 24-hour symptom relief.

Standard Dosing and Frequency

The medicine is administered once daily (qDay). The standard recommended doses are as follows:

Population Group Standard Recommended Dose Frequency
Adults and Adolescents (ge 12 years) 5 mg (one tablet) Once daily
Children 6 to 11 years of age 2.5 mg Once daily
Children 12 months to 5 years of age 1.25 mg Once daily

The standard regimens reflect clinical applications for the management of allergic symptoms.


Administration Conditions and Adjustments

Flynise may be taken without regard to meals (with or without food). Specific administration instructions exist for the various dosage forms:

  • Orodispersible Tablets: Must be placed on the tongue, where they disintegrate rapidly, and should be taken immediately after removal from the blister pack.
  • Oral Solution: The correct dose must be measured using a calibrated measuring device to ensure accuracy.

Official guidelines mandate dosage modifications for certain adult populations. For patients with severe renal or hepatic impairment, the recommended starting dose is 5 mg every other day.


Treatment Duration

Treatment duration is typically based on the nature of the symptoms. For Intermittent Allergic Rhinitis (symptoms lasting less than four days per week or less than four weeks), treatment can be stopped once symptoms resolve. For Persistent Allergic Rhinitis, continued treatment may be proposed during periods of allergen exposure.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Flynise

The research evidence for Flynise (desloratadine) is primarily built upon findings from authorized governmental and scientific sources, including systematic reviews and controlled clinical trials. These studies were conducted to evaluate Flynise's use in specific allergic conditions characterized by fluctuating or episodic manifestations.


Evidence for Use in Allergic Rhinitis

Research for allergic rhinitis (AR) is based on numerous short-term, placebo-controlled Randomized Controlled Trials (RCTs). These studies were conducted during periods of increased symptom activity and research examined how symptoms change over time in Adults and Adolescents. Researchers included both those with Seasonal Allergic Rhinitis (SAR) and Perennial Allergic Rhinitis (PAR).

The primary focus of these trials was studied for changes in outcomes related to physical discomfort, specifically the scores used to measure symptoms like sneezing, runny nose, and nasal congestion. The findings describe patterns observed in the studies where the groups receiving the medicine and the placebo showed different measurements in symptom scores over the study period. Studies report how symptoms evolved in the observed populations, contributing to the broader evidence landscape concerning short-term changes.


Evidence for Use in Chronic Urticaria

Clinical evaluation of Flynise for Chronic Idiopathic Urticaria (CIU) is based on multiple placebo-controlled RCTs. These studies typically were evaluated in adults and adolescents with conditions involving periods of heightened symptoms of hives and itching, usually lasting for about four to six weeks.

Research examined outcomes capturing phases of heightened symptom activity, such as the severity of the itching (pruritus) and the number and size of the wheals. The data show patterns related to symptom control that was observed in some studies relatively soon after the first use and were observed across the 6-week observation interval. Findings help contextualize how patients reported their experience of symptom change in the conditions where symptoms may vary in intensity.


What Remains Uncertain About Flynise Research

While substantial research exists, there are recognized limitations that evidence highlights what is known — and what is still uncertain.

Follow-up durations were limited in the core controlled trials; therefore, the long-term effectiveness and maintenance of effect over periods greater than six weeks are not fully established by the highest-quality evidence. Comparative evidence is lacking for comprehensive, head-to-head trials against all similar medications for every approved use.

Frequently Asked Questions (FAQ)

Common questions about Flynise (FAQ)


Q: Is it okay to have alcohol while taking Flynise?

Official clinical studies have examined the combined use of Flynise and alcohol and did not find that Flynise increased alcohol's performance-impairing effects. However, regulatory post-marketing data includes reports of alcohol intolerance. For this reason, official product information highlights the need for caution.


Q: Can Flynise affect my mood?

Regulatory documents and post-marketing surveillance reports list some psychiatric effects as potential adverse events, although they are generally considered uncommon. These reports, primarily noted in pediatric studies, have included effects such as irritability, insomnia, and emotional lability.


Q: Is it common to feel fatigue or dizziness when starting Flynise?

Studies indicate that fatigue and dry mouth were among the most frequent side effects reported by patients in clinical trials, occurring slightly more often than those taking an inactive treatment (placebo). The side effects reported were generally mild, and official product information provides a complete list of possible side effects.


Q: What are the most commonly reported side effects of Flynise?

According to clinical trial data, the most frequently reported side effects that occurred more often with Flynise than with placebo were fatigue, dry mouth, and headache. In these studies, the reported incidence rates for these three effects were very low, at less than 2%.


Q: Can Flynise affect hormonal birth control?

Official interaction studies have been conducted to determine the co-administration effects of Flynise with hormonal contraceptives. Regulatory reviews of formal interaction studies indicate that no clinically significant interaction has been documented between this medication and hormonal birth control.


Q: Are there any vitamins or supplements that interact with Flynise?

Official regulatory documents do not list specific formal interactions with most common vitamins or nutritional supplements. However, official patient information recommends discussing all nutritional products, vitamins, and supplements, including herbal products, with a healthcare professional.


Q: Can Flynise cause issues with driving or operating machinery?

Flynise is classified as a non-sedating antihistamine, meaning it does not readily cross into the brain to cause drowsiness for most individuals. Despite this, official product information highlights the need for caution when performing tasks requiring mental alertness, such as driving or operating machinery, until the individual response to the medication is known.


Q: What kind of monitoring is typically needed while on Flynise?

Official regulatory guidelines advise that caution and potential dosage adjustments may be necessary for adult patients who have severe impairment of kidney (renal) or liver (hepatic) function. These conditions can cause the concentration of Flynise in the body to increase.


Q: Can teenagers or children use Flynise?

Yes, official product information indicates that Flynise has been approved by regulatory agencies for use in different pediatric age groups, starting from 6 months of age. There are specific dosage forms and strengths approved for infants, children, and adolescents 12 years and older.


Q: Is Flynise considered a long-term or short-term medication?

The decision on the duration of Flynise use is based on the specific condition being managed. For intermittent allergic rhinitis (short periods of symptoms), the treatment may be discontinued once symptoms resolve. For persistent allergic rhinitis or chronic hives, continued daily treatment may be advised during periods of allergen exposure or symptom activity.


Q: What kind of studies have been done on Flynise?

Flynise received regulatory approval based on data gathered from high-standard, randomized, double-blind, placebo-controlled clinical trials. These studies, detailed in the official product labeling, assessed how effective and safe the medication was for patients with allergic rhinitis and chronic hives (urticaria).


Q: Has Flynise been studied in older adults?

Pharmacokinetic studies, which examine how the drug is processed in the body, have included subjects who are 65 years and older. Study findings suggest that no change in the recommended dose is typically necessary based on age alone. However, official information advises caution for older adults who also have kidney or liver impairment.


Q: Is Flynise available as a generic version?

Regulatory approval documents confirm that generic versions of the tablet formulation of Flynise’s active ingredient have been approved by the FDA. This indicates that the active substance is widely available in generic form.


Q: What happens if I miss a dose of Flynise?

Official patient information provides guidance if a dose is missed: patient information states that a missed dose may be taken as soon as it is remembered. However, if it is nearly time for your next scheduled dose, the regulatory guidance is to skip the missed dose. Patient information cautions against taking a double dose to maintain the scheduled regimen.


Q: Does Flynise cause weight gain or weight loss?

Weight changes are not listed as common side effects in the core clinical trials for Flynise. However, official post-marketing surveillance reports include 'weight increased' and 'appetite increased' in the list of reported adverse reactions, although the frequency of these particular effects is not established.


Q: Is Flynise known to affect sleep patterns?

While Flynise is generally considered non-sedating, official adverse event reports list both sleepiness (somnolence) and difficulty sleeping (insomnia) as reactions. These effects were noted primarily in studies involving specific pediatric populations.


Q: What should I do if the side effects of Flynise seem mild?

Patient information advises that common, mild side effects like headache or dry mouth may occur and typically do not require immediate medical attention. However, if any mild side effects continue, worsen, or become bothersome, official guidance notes that a healthcare provider should be consulted.


Q: Is sun sensitivity a reported side effect of Flynise?

Post-marketing surveillance reports list photosensitivity, which is an increased sensitivity to sunlight, as a potential adverse reaction. The frequency of this particular effect has not been established in controlled clinical trials.


Q: How long does Flynise stay in your system after stopping it?

The time it takes for a medication to leave the body is governed by its elimination half-life, which is a pharmacokinetic property. For Flynise, the active ingredient has an average elimination half-life of approximately 27 hours in most individuals.


Q: How long does it usually take to notice an effect from Flynise?

While individual response times can vary, pharmacokinetic studies indicate that the active ingredient reaches its highest concentration in the blood, known as the peak plasma concentration, about three hours after taking the oral dose. This peak concentration is associated with the expected therapeutic action of the medication.


Q: What if I take Flynise at a slightly different time each day?

Because Flynise is designed to provide continuous, 24-hour symptom relief, regulatory patient information highlights the importance of taking the medication around the same time every day. This helps ensure a consistent level of the active ingredient is maintained in the body.


Q: How does Flynise affect blood pressure?

Clinical trials comparing Flynise to placebo did not indicate any consistent or clinically relevant changes in blood pressure. While rare post-marketing reports have included heart rhythm changes, the official pharmacological data supports the observation of no significant change in blood pressure.


Q: Do I have to take Flynise every day?

Whether Flynise is taken every day depends on the condition it is treating. For persistent conditions, continued daily treatment may be required. For intermittent symptoms, regulatory guidelines state that treatment may be discontinued once symptoms resolve and re-initiated if symptoms reappear.


Q: What if I accidentally took two doses back-to-back?

Official regulatory studies examined high doses of Flynise, up to nine times the recommended daily amount, which did not result in clinically serious adverse events. However, patient information cautions against taking a double dose. Maintenance of the recommended once-daily regimen is a key element of the official administration instructions.

How should Flynise be stored and disposed of?

How to Store and Dispose of Flynise

The storage and disposal conditions for Flynise (Desloratadine) are defined by regulatory requirements to ensure product quality and safe handling.

Required Storage and Protection

Flynise must be stored at Controlled Room Temperature, which ranges from 20 C to 25 C (68 F to 77 F), with temporary excursions permitted up to 30 C (86 F). The product must be kept in its original package to protect it from moisture and direct light. It is strictly prohibited to refrigerate or freeze the medication. For child safety, Flynise must always be stored out of the sight and reach of children.

Disposal Requirements

Unused or expired Flynise should not be disposed of in household waste or wastewater. Disposal must follow the local or national requirements for pharmaceutical waste and typically involves returning the product to a pharmacy or designated collection site.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Flynise found in:

A-Z Index: